Navigation Links
Boca Pharmacal Receives FDA Approval for Carbinoxamine Maleate 4 mg Tablet
Date:6/2/2008

CORAL SPRINGS, Fla., June 2 /PRNewswire/ -- Boca Pharmacal, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Pamlab's Palgic(R) 4mg Tablet (Carbinoxamine Maleate 4 mg Tablet). The Company plans to launch its product immediately.

Carbinoxamine Maleate 4mg Tablet is indicated to treat seasonal and perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and food, mild, uncomplicated allergic skin manifestations of urticaria and angioedema, dermatographism, as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after acute manifestations have been controlled and amelioration of the severity of allergic reactions to blood or plasma.

"In a world of rising healthcare costs we pride ourselves on our ability to offer lower volume items that may have been overlooked by the generic pharma giants," commented Robert J. Edwards Jr., CEO. "This is another example of our continuing effort to provide affordable prescription drugs. Carbinoxamine Maleate 4mg Tablet is one more approval stemming from strong R&D and a robust product pipeline. We are pleased with our success and look forward to more filings and approvals this year."

Founded in 1998 Coral Springs, FL based Boca Pharmacal is an emerging specialty pharmaceutical company that develops, manufactures, markets, and distributes generic pharmaceutical products.


'/>"/>
SOURCE Boca Pharmacal, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mission Pharmacal Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia in the U.S.
2. Boca Pharmacal Receives FDA Approval for Carbinoxamine Oral Solution
3. Mission Pharmacal Launches CitraNatal(TM) Prescription Prenatal Vitamin Line
4. Mission Pharmacal Congratulates Exemplary Womens Health Researchers
5. PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL
6. Edwards Lifesciences Receives Additional Questions From the FDA About the LifeStent Product Line
7. Lupin Receives USFDA Approval for Topiramate Tablets
8. Ohio State receives $34M NIH grant
9. IPRO Receives Google Advertising Grant
10. Harvard Medical School receives major NIH grant for galvanizing translational science
11. BUMC, BMC receives Clinical and Translational Science Award from NIH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
Breaking Medicine Technology: